CEO: Jay Shepard

Advent Contact: Shahzad Malik

Long acting human growth hormone

Versatis' lead product SomavaratanTM is a novel long-acting recombinant human growth hormone for the treatment of paediatric growth hormone deficiency. SomavaratanTM dosed only twice a month has shown equivalence to once daily growth hormone treatment in children over a period of two years and is now in a Phase III registration study. SomavaratanTM is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections to improve compliance and outcome.

Advent invested in the Series B in 2011. Versartis listed on NASDAQ in 2014 (NASDAQ:VSAR).


Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting

Versartis Initiates Global Phase 3 Study of VRS-317 in Children With Growth Hormone Deficiency